NxStage System One, as the world's first portable home hemodialysis device certified by the FDA, has become a technical benchmark in the HHD field. This study focuses on the Nxstage System One home hemodialysis equipment, comprehensively analyzes its technical architecture, and deeply explores its clinical efficacy. By disassembling the technical architecture of the equipment, analyzing its hardware composition and working principle, and clarifying its unique design. In terms of clinical efficacy, by integrating multi-dimensional data and comparing it with traditional hemodialysis methods, the performance of this equipment in terms of therapeutic effect, improvement of quality of life and complications is expounded. Studies have shown that the innovation in the technical architecture of Nxstage System One brings new possibilities for clinical applications and has significant advantages in improving the quality of life of patients and optimizing treatment effects.

Hao Lu, Bo Cao, Wanting Chen. Research on the Technical Architecture and Clinical Efficacy of Nxstage System One Home Hemodialysis Equipment. International Journal of World Medicine (2025), Vol. 6, Issue 1: 56-62. https://doi.org/10.38007/IJWM.2025.060107.

[1]Susumu T .Future home hemodialysis-advantages of the NxStage System One.[J].Contributions to nephrology,2012,177117-26.

[2]Treu D, Ashenuga M, Massingham K, et al. An Innovative Approach to Minimizing Downtime in Continuous Kidney Replacement Therapy[J].Asaio Journal,2023,69(6):e250-e255.

[3]Clark W R, Turk Jr J E. Approaches to quotidian dialysis: the NxStage System One[C]//Seminars in Dialysis. Oxford, UK: Blackwell Science Inc,2004,17(2):167-170.

[4]Brunati C C M, Gervasi F, Casati C, et al. Phosphate and calcium control in short frequent hemodialysis with the NxStage system one cycler: mass balance studies and comparison with standard thrice-weekly bicarbonate dialysis[J].Blood Purification,2018,45(4):334-342.

[5]Kraus M, Burkart J, Hegeman R, et al. A comparison of center‐based vs. Home-based daily hemodialysis for patients with end‐stage renal disease[J].Hemodialysis International,2007,11(4):468-477.

[6]Maria C C B ,Francesca G ,Costanza C , et al.Phosphate and Calcium Control in Short Frequent Hemodialysis with the NxStage System One Cycler: Mass Balance Studies and Comparison with Standard Thrice-Weekly Bicarbonate Dialysis.[J].Blood purification,2018,45(4):334-342.

[7]Brunati C C M, Gervasi F, Cabibbe M, et al. Single session and weekly beta 2-microglobulin removal with different dialytic procedures: comparison between high-flux standard bicarbonate hemodialysis, post-dilution hemodiafiltration, short frequent hemodialysis with nxstage technology and automated peritoneal dialysis[J].Blood Purification,2019,48(1):86-96.

[8]Rocha S, Nascimento H, Valente M J, et al. SP637 Inflammation And Cell-Free Dna As Biomarkers For The Outcome Of End Stage Renal Disease Patients[J].Nephrology Dialysis Transplantation,2019,34(Supplement_1):gfz103.SP637.

[9]Razavi S A, Still M D, White S J, et al. Comparison of circuit patency and exchange rates between 2 different continuous renal replacement therapy machines[J].Journal of critical care,2014,29(2):272-277.

[10]Brunelli S M, Wilson S M, Ficociello L H, et al. A comparison of clinical parameters and outcomes over 1 year in home hemodialysis patients using 2008K@ home or NxStage system one[J].ASAIO Journal,2016,62(2):182-189.